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Abstract
Anemia of cancer (AC) may contribute to cancer-related fatigue and impair quality of life. Improved understanding of the
pathogenesis of AC could facilitate better treatment, but animal models to study AC are lacking. We characterized four
syngeneic C57BL/6 mouse cancers that cause AC. Mice with two different rapidly-growing metastatic lung cancers
developed the characteristic findings of anemia of inflammation (AI), with dramatically different degrees of anemia. Mice
with rapidly-growing metastatic melanoma also developed a severe anemia by 14 days, with hematologic and inflammatory
parameters similar to AI. Mice with a slow-growing peritoneal ovarian cancer developed an iron-deficiency anemia, likely
secondary to chronically impaired nutrition and bleeding into the peritoneal cavity. Of the four models, hepcidin mRNA
levels were increased only in the milder lung cancer model. Unlike in our model of systemic inflammation induced by heat-
killed Brucella abortus, ablation of hepcidin in the ovarian cancer and the milder lung cancer mouse models did not affect
the severity of anemia. Hepcidin-independent mechanisms play an important role in these murine models of AC.
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Introduction
Anemia is a remarkably common complication of cancer,
occurring in .30% of untreated patients [1]. The incidence of
anemia is further increased by cancer treatment, including
chemotherapy and radiation. Anemia of cancer (AC) correlates
with poor WHO performance status and quality of life [2,3].
Effective treatment of AC decreases subjective fatigue in cancer
patients [4]. In addition to the effects on quality of life, the
presence of AC may be an independent negative prognostic factor
[5].
The etiology of AC is multifactorial and likely varies with the
origin of the primary tumor, as well as the chronicity of the disease
process. Important contributing factors include iron deficiency
secondary to bleeding or nutritional deficiencies [6], hemolysis due
to immune phenomena, activation of clotting cascades or
abnormal tumor-associated vasculature [7], impaired erythropoi-
esis secondary to inadequate erythropoietin production or
depressed response of the erythroid marrow to erythropoietin
[8], and direct invasion of the marrow by tumor cells with
disruption of the erythropoietic environment. A particularly
important contributor to AC is inflammation, as AC shares many
of the characteristics of anemia of inflammation (AI). AI is a
normocytic, normochromic anemia with a shortened erythrocyte
lifespan and depressed erythropoiesis. AI is also characterized by a
derangement of systemic iron homeostasis characterized by
hypoferremia with intact iron stores [9] and decreased availability
of iron for erythrocyte production.
Hepcidin, a 25-amino acid peptide hormone produced primar-
ily by hepatocytes [10], is the primary regulator of iron
homeostasis in health and during inflammation [11]. Hepcidin
acts by binding to ferroportin, the sole known cellular iron
exporter, displayed on the surface of cells that supply iron to
plasma: macrophages, hepatocytes and enterocytes. Hepcidin
binding to ferroportin leads to ferroportin endocytosis and
degradation [12], limiting the flow of iron into plasma and thus
reducing iron availability for erythropoiesis. During inflammation,
hepcidin expression is strongly induced, largely by IL-6 [13] via
the JAK-STAT pathway [14–16] and this hepcidin excess is
thought to contribute to the development of AI. Interestingly, IL-6
has been noted to be increased in multiple tumor types, including
lung cancer [17] and ovarian cancer [18]. The extent to which
increased hepcidin production contributes to AC has not been
directly tested by genetic ablation of hepcidin, partially because of
the paucity of mouse models of AC.
Despite the high prevalence of AC with its negative effects on
quality of life and survival, few animal models have been
developed for its study. We have characterized four syngeneic
C567BL/6 mouse models of cancer: two rapidly-growing models
of lung cancer, one rapidly-growing model of melanoma, and one
slow-growing model of ovarian cancer. After a comprehensive
examination of hematologic, iron, and inflammatory parameters
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of these models, we investigated the extent of hepcidin involve-
ment in the development of AC in two of these models by
comparing C57BL/6 mice to hepcidin knockout mice on the same
strain background.
Materials and Methods
Ethics Statement
All animal work and care were performed under the guidelines
of the University of California, Los Angeles (UCLA) Chancellor’s
Animal Research Committee (ARC). Specific approval for the
mouse experiments was obtained with the protocol #2008-129-12
titled ‘‘The role of IL-6 and hepcidin in anemia of cancer.’’ All
reasonable efforts were made to ameliorate suffering, including
anesthesia for painful procedures.
Animal models of anemia of cancer
All animal studies were approved by the Animal Research
Committee at University of California, Los Angeles (UCLA). 6-
week-old C57BL/6J mice were obtained from Charles River
Laboratories (Wilmington, MA) or The Jackson Laboratories (Bar
Harbor, ME). For the three rapidly-growing cancer models, male
and female wild-type (WT) mice were placed on an iron-sufficient
diet (20 ppm iron, Harlan Teklad, Indianapolis, IN) for 2 weeks
before injection of tumor cells or saline. The same diet was used
through the remainder of the experiment. This dietary condition-
ing was applied because the high iron content of standard chow
(approximately 7–8 times the daily requirement) dramatically
increases hepcidin expression and renders it unresponsive to
inflammatory stimuli [19]. Additionally, dietary iron absorption in
mice accounts for as much as 50% of the daily iron fluxes in mice
fed standard chow, but only ,5–10% in humans [20]. This
increased dietary iron absorption in mice may diminish the
relative contribution of iron recycling by macrophages [21] and
leads to progressive iron loading. Thus, the reduction of dietary
iron content in the mouse chow was designed to model iron fluxes
of human homeostasis. For the slow-growing model of ovarian
cancer, female mice were maintained on an iron-sufficient diet of
either 20 ppm iron or 50 ppm iron.
To generate a metastatic lung cancer model, animals were
injected intraperitoneally (IP) with 0.16106–0.56106 murine TC-
1 or Lewis lung carcinoma (LLC) cells (ATCC, Manassas, VA).
Because these are metastatic tumor cells, and we were investigat-
ing the systemic response to these cancers, we opted to perform
intraperitoneal injections rather than incubating the tumor cells in
their primary organ. The LLC cells were cultured as adherent cells
in Dulbecco’s modified Eagle media (DMEM) (Life Technologies,
Grand Island, NY) supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin G-streptomycin, and the TC-1 cells were
cultured as adherent cells in RPMI 1640 (Life Technologies,
Grand Island, NY) supplemented with 10% FBS and 1% penicillin
G-streptomycin. On the day of treatment, tumor cells were
resuspended in phosphate buffered saline (PBS), counted with a
hematocytometer, and injected in a volume of 500 mL PBS.
Control mice were injected IP with 500 mL PBS. Mice were
euthanized at 13–15 days, and blood, liver, and spleen were
collected at necropsy.
For the mouse model of metastatic melanoma, animals were
injected IP with 0.16106–0.36106 B16-F10 cells (ATCC, Manas-
sas, VA). The B16-F10 cells were cultured as adherent cells in
DMEM (Life Technologies, Grand Island, NY) supplemented with
10% FBS and 1% penicillin G-streptomycin. On the day of
treatment, tumor cells were resuspended in PBS, counted with a
hematocytometer, and injected in a volume of 500 mL PBS.
Control mice were injected IP with 500 mL PBS. Mice were
euthanized at 14 days, and blood and liver were collected at
necropsy.
For peritoneally disseminated ovarian cancer, animals were
injected IP with 16106 ID8 cells that were generously provided by
Dr. Oliver Dorigo. The metastatic ID8 cell line was derived from
spontaneous malignant transformation of C57BL/6 mouse ovar-
ian surface epithelium cells in vitro [22]. The cells were cultured in
DMEM supplemented with 10% FBS and 1% penicillin G-
streptomycin. On the day of treatment, tumor cells were
resuspended in PBS, counted with a hematocytometer, and
injected in a volume of 500 mL PBS. Control mice were injected
IP with 500 mL PBS. Mice were euthanized at 18.5 weeks.
To study the role of hepcidin in anemia of cancer, we used male
and female hepcidin-1 knockout (HKO) mice for the TC-1 model,
and female HKO mice for the ID8 model. HKO mice were
originally provided to our laboratory by Dr. Sophie Vaulont [23]
and were backcrossed onto the C57BL/6 background as
previously described [24]. For this portion of the study, HKO
mice underwent dietary conditioning to prevent the development
of iron overload and maintain iron levels comparable to those of
WT mice. At weaning, the HKO mice were started on reduced-
iron diets (4 ppm or 20 ppm) for about 2 weeks to prevent the
massive iron loading characteristic of this knockout mouse. From
the time of injection, the mice were maintained on a 20 ppm iron
diet for the remainder of the study. For the TC-1 model, HKO
mice were injected and euthanized as described above for the WT
mice. For the ID8 model, HKO mice were euthanized at 16.5
weeks.
Measurement of iron parameters and erythropoietin
Serum iron and liver non-heme iron concentrations were
measured by a colorimetric assay for iron (Sekisui Diagnostics;
Lexington, MA) as previously described [20].
Hematologic studies
Complete blood counts were obtained with a HemaVet blood
analyzer (Drew Scientific; Waterbury, CT). To assess iron-
restricted erythropoiesis, zinc protoporphyrin (ZPP) was measured
using a hematofluorometer (AVIV; Lakewood, NJ). Reticulocytes
were counted by flow cytometry. Blood (5 ml) was added to 1 ml of
thiazole orange in PBS with 0.1% sodium azide (PBS-azide, BD
Bioscience; San Jose, CA) and incubated at room temperature for
1–3 h. As an unstained control, blood was added to PBS-azide
without thiazole orange. The percentage of red-fluorescent
reticulocytes (Retic %), was measured by flow cytometry at the
UCLA Jonsson Comprehensive Cancer Center (JCCC) and
Center for AIDS Research Flow Cytometry Core Facility that is
supported by National Institutes of Health awards CA-16042 and
AI-28697, and by the JCCC, the UCLA AIDS Institute, and the
David Geffen School of Medicine at UCLA. Unstained controls
were used to establish a gate to exclude background fluorescence.
The results are expressed as the reticulocyte product index:
RPI =Retic %6Hgb/baseline Hgb.
RNA isolation and real-time quantitative PCR
Total RNA was isolated from liver and analyzed by real-time
RT-PCR as described previously [25].
Murine b-actin was used as a housekeeping mRNA control.
Primers are listed in Table S1.
Mouse Models of Anemia of Cancer
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Histocytopathology
Peripheral blood smears were performed using 10 mL whole
blood at the time of necropsy, and prepared with Wright-Giemsa
stain (Fisher; Hampton, NH).
Statistics
SigmaStat was used for all statistical analyses (Systat Software;
Point Richmond, CA). For the melanoma, lung cancer, and
hepcidin KO models, normally distributed data were compared
using Student t-test. Measurements that were not normally
distributed were compared by the nonparametric Mann-Whitney
rank sum test. P,0.05 was considered statistically significant. ID8
wild-type mouse data was initially analyzed using Two Way
ANOVA, with ID8/saline injection and diet iron as the two
variables affecting outcome. This statistical analysis showed no
significant interaction effect between the two variables. The ID8
wild-type data is presented using Student t-test for parametric
data, and Mann-Whitney rank sum test for nonparametric data.
Correlation measurements were obtained by Pearson Correlation.
Both male and female WT and HKO mice were used for the
three rapidly-growing cancer mouse models. Analysis of key
hematologic parameters, including hemoglobin and serum iron,
showed that there was no significant difference between the male
and female mice. Thus, we are presenting combined male and
female data.
Results
Mice with metastatic lung cancers develop anemia with
reticulocytosis and iron restriction
We generated two models of metastatic lung cancer by injecting
the syngeneic cancer cell lines, TC-1 and LLC, into the peritonea
of mice. Control mice received PBS. Before euthanasia at 14 d
after injection, all the tumor mice displayed signs consistent with
systemic illness secondary to tumor load, including lethargy, poor
grooming, and ascites. Necropsy revealed intraperitoneal masses
in most of the mice. Hemoglobin was lower in the tumor mice as
compared to controls (Fig. 1A) (LLC 7.8 g/dL vs. PBS 15.6 g/dL,
P,0.001; TC-1 14.2 g/dL vs. PBS 15.6 g/dL, P= 0.029). The
anemic tumor mice had increased reticulocytosis as compared to
the controls (Fig. 1B) (RPI in LLC 10.7 vs. PBS 2.4, P,0.001; TC-
1 6.1 vs. PBS 2.4, P,0.001). Of note, the LLC mice had lower
hemoglobin levels than TC-1 mice (P,0.001) and greater
reticulocytosis (P = 0.006).
When insufficient iron is available for erythropoiesis, increased
levels of zinc are incorporated into the protoporphyrin ring.
Therefore, zinc protoporphyrin (ZPP) levels are a good indicator
of iron-restricted erythropoiesis [26]. ZPP levels in tumor-bearing
mice were increased compared to controls, indicating iron-
restricted erythropoiesis (Fig. 2A) (LLC 160 vs. PBS 84,
P,0.001; TC-1 136 vs. PBS 84, P,0.001). LLC mice had a
trend towards higher ZPP levels than the less anemic TC-1 mice
(P = 0.129). Tumor-bearing mice had hypoferremia as indicated
by a serum iron assay (Fig. 2B) (LLC 11.5 mmol/L vs. PBS
39.8 mmol/L, P= 0.004; TC-1 20.8 mmol/L vs. PBS 39.8 mmol/
L, P= 0.031). In order to determine whether this was due to iron
sequestration, as would be seen in anemia of inflammation, rather
than iron-deficiency anemia secondary to malnutrition or bleed-
ing, total body iron stores were estimated using liver and spleen
tissue iron measurements. Both lung tumor models had higher
liver nonheme iron content than controls (Fig. 2C) (LLC
8.9 mmole Fe/g vs. PBS 1.5 mmole Fe/g, P,0.001; TC-1
3.9 mmole Fe/g vs. PBS 1.5 mmole Fe/g, P= 0.002). LLC mice
also had higher spleen nonheme iron content than controls, and
TC-1 mice had comparable spleen iron content (Fig. 2D) (LLC
15.9 mmole Fe/g vs. PBS 10.4 mmole Fe/g, P= 0.039).
Mice with metastatic lung cancers manifest
inflammation, but hepcidin is increased only in the less
severe model
In order to evaluate the contribution of inflammation and
hepcidin activity to the development of anemia in our cancer
models, we measured the hepatic mRNA concentrations of SAA-1
and hepcidin. SAA-1 is a hepatic acute phase reactant that is
known to be increased in response to inflammation and certain
cytokines, particularly IL-6 [27]. As IL-6 is thought to be an
important cause of the anemia of inflammation by inducing
hepcidin expression [19], we used SAA-1 measurements as an
indicator of IL-6 activity. On day 14, both TC-1 and LLC mice
had elevated liver SAA-1 mRNA levels as compared to controls
(Fig. 3A). LLC mice had a .75-fold increase over the PBS mice
(P= 0.001), and TC-1 mice had a .340-fold increase (P= 0.002).
On day 14, the mildly anemic TC-1 mice had mildly elevated liver
hepcidin mRNA levels as compared to controls (.26, P = 0.012)
(Figure 3B), while the more severely anemic LLC mice had lower
hepcidin levels (P = 0.022), perhaps because of the counter-
regulatory effect on hepcidin of moderate anemia and the
resulting erythropoietic stimulus [28]. To assess the influence of
inflammation on hepcidin mRNA expression, we evaluated the
correlation between the levels of SAA-1 mRNA and correspond-
ing hepcidin mRNA levels in individual mice but the correlation
was weak [data not shown]. Despite much higher SAA-1 levels in
the tumor-bearing mice than in controls, indicative of tumor-
induced inflammation, hepcidin mRNA concentrations were not
increased proportionally in TC-1-bearing mice and were even
decreased in LLC-bearing mice. These data suggest that other
factors may counteract the effect of inflammation on hepcidin
synthesis, and these could include anemia and increased erythro-
poiesis.
Hepcidin mRNA levels were also measured in the tumors to
determine whether tumor hepcidin expression may be contribut-
ing to the development of anemia of cancer. Neither TC-1 nor
LLC tumors had detectable hepcidin expression, illustrating that
these tumors do not directly contribute to systemic hepcidin levels.
Mice with melanoma develop anemia with iron-restricted
erythropoiesis and inflammation
We next generated a mouse model of metastatic melanoma by
injecting a melanoma cell line, B16-F10, into the peritonea of
mice. Control mice received PBS. Before euthanasia 14 d after
injection, the tumor mice displayed signs consistent with systemic
illness and tumor burden, including lethargy and ascites. Complete
blood count analysis revealed a marked anemia in the melanoma
mice as compared to controls (Fig. 4A) (B16-F10 Hgb 8.2 g/dL vs.
PBS Hgb 15.6 g/dL, P,0.001). The tumor mice also developed a
robust reticulocytosis .46 that of their control counterparts
(Fig. 4B). Melanoma mice demonstrated significant iron-restricted
erythropoiesis with a .2-fold increase in ZPP levels as compared
to controls (Fig. 4C).
On day 14, the melanoma mice had a dramatic increase (.600-
fold) in SAA-1 mRNA as compared to controls, indicating robust
inflammation (Fig. 4D). Hepcidin mRNA levels were suppressed in
the tumor mice as compared to controls (Fig. 4E). Because this
tumor elicited an anemia with very similar characteristics to that
caused by metastatic LLC lung cancer, its effect on iron
homeostasis was not characterized further.
Mouse Models of Anemia of Cancer
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Mice with ovarian cancer develop iron-deficiency anemia
We also analyzed the development of anemia in mice with a
slow-growing ovarian cancer by injecting the syngeneic ovarian
cancer cell line ID8 into the peritonea of mice. The ID8-injected
and PBS-injected control mice were sacrificed 18.5 weeks after the
date of injection. At this time, all the tumor-bearing mice displayed
signs consistent with systemic illness, including lethargy, poor
grooming, and ascites. Necropsy revealed visible intraperitoneal
Figure 1. Mice with metastatic lung cancer develop anemia with reticulocytosis. C57BL/6 mice were injected intraperitoneally with
0.16106–0.56106 murine TC-1 or Lewis lung carcinoma (LLC) cells and euthanized after 14 days. Compared to controls, the tumor-bearing mice have:
(A) decreased hemoglobin; (B) increased reticulocytosis. N = 8–19 mice per treatment and control group. *P,0.05, **P,0.001; P by Mann-Whitney
rank sum test. Bars and error bars are median 675th/25th percentile.
doi:10.1371/journal.pone.0093283.g001
Figure 2. Mice with metastatic lung cancer have iron-restricted erythropoiesis with hypoferremia and increased tissue iron stores.
C57BL/6 mice were injected intraperitoneally with TC-1 or LLC cells and euthanized after 14 days. Both tumor-bearing mouse models show: (A)
elevated ZPP levels compared to controls, indicating iron-restricted heme synthesis; (B) hypoferremia; (C) increased liver iron. (D) The LLC-bearing
mice have increased spleen iron, and the TC-1-bearing mice have a trend towards increased spleen iron, TC-1 vs. PBS, P = 0.381. N= 8–19 mice per
treatment and control group. *P,0.05, **P,0.001; P by Mann-Whitney rank sum test. Bars and error bars are median 675th/25th percentile.
doi:10.1371/journal.pone.0093283.g002
Mouse Models of Anemia of Cancer
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masses in the majority of the mice with bloody ascites in many.
Hemoglobin was lower in tumor-bearing mice as compared to
controls (Fig. 5A) (ID8 10.4 g/dL vs. PBS 11.25 g/dL, P= 0.040).
PBS mice themselves had moderately decreased hemoglobin
levels, likely as a consequence of having been fed a reduced-iron
diet for 18 weeks. The tumor-bearing mice had elevated ZPP
levels as compared to controls, indicating iron-restricted erythro-
poiesis (Fig. 5B) (ID8 162 vs. PBS 129, P = 0.008). Total body iron
stores were evaluated using liver and spleen tissue iron measure-
ments. The ID8-bearing mice had lower liver and spleen iron
content than controls (Fig. 5C,D) (ID8 liver iron 8.1 mmole Fe/g
vs. PBS liver iron 14.9 mmole Fe/g, P = 0.041; ID8 spleen iron
63.1 mmole Fe/g vs. PBS spleen iron 138.5 mmole Fe/g,
P= 0.011). Thus this ovarian tumor model develops anemia with
frank iron deficiency, likely partially secondary to bleeding into the
peritoneal cavity and impaired nutrition.
Mice with ovarian cancer have suppressed hepcidin
levels responsive to liver iron stores
At 18.5 weeks, ID8 mice had depressed liver hepcidin mRNA
levels as compared to controls (Fig. 6A) (ID8 0.20 vs. PBS 14.08,
P= 0.013), as well as comparable SAA-1 levels to controls (Fig. S1)
(P = 0.361), indicating that inflammation and hepcidin do not play
a major role in the development of this anemia. In addition,
figure 6B shows a significant positive correlation between hepcidin
and liver iron levels, which indicates appropriate hepcidin
suppression with the development of iron-deficiency anemia in
this ovarian tumor model (ID8 hepcidin vs. liver iron, R2= 0.64,
P= 0.017).
The development of anemia in the mouse tumor models
is not secondary to microangiopathic hemolysis
The list of potential causes of anemia in cancer models includes
microangiopathic hemolysis or shearing of erythrocytes, which can
also be seen in inflammatory anemias [6]. The peripheral blood
smears of the tumor-bearing mice showed no schistocytes or
erythrocyte fragments. Figure 7B shows a nearly normal blood
smear of the TC-1 model, with minimal membrane irregularities.
Figures 7C and 7D show that the more anemic LLC and ID8
models do have more severe erythrocyte abnormalities, including
teardrop cells and central pallor, but again without a significant
Figure 3. TC-1 and LLC tumor-bearing mice show evidence of systemic inflammation but only TC-1 has increased hepcidin mRNA.
By day 14, (A) both tumor models have increased levels of liver SAA-1 mRNA; (B) TC-1-bearing mice have increased liver hepcidin mRNA levels
compared to controls, and LLC-bearing mice have decreased hepcidin. N= 8–19 mice per treatment and control group. *P,0.05; P by Mann-Whitney
rank sum test. Bars and error bars are median 675th/25th percentile.
doi:10.1371/journal.pone.0093283.g003
Figure 4. The melanoma-bearing mice develop anemia with
iron-restricted erythropoiesis and inflammation. C57BL/6 mice
were injected intraperitoneally with 0.16106–0.36106 B16-F10 cells, and
euthanized after 14 days. The melanoma-bearing mice develop: (A) a
significant anemia; (B) increased reticulocytosis compared to controls;
(C) elevated zinc protoporphyrin (ZPP) levels compared to controls,
indicating iron-restricted heme synthesis; (D) increased levels of liver
SAA-1 mRNA, a marker of inflammation and IL-6 activity; (E) lower levels
of hepcidin mRNA. N= 8–11 mice per treatment and control group.
*P,0.05, **P,0.001; P by Mann-Whitney rank sum test. Bars and error
bars are median 675th/25th percentile.
doi:10.1371/journal.pone.0093283.g004
Mouse Models of Anemia of Cancer
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number of schistocytes that would indicate a contribution of
microangiopathic hemolysis to anemia. [29]
Anemia is not attenuated in hepcidin-ablated TC-1- or
ID8-bearing mice
In order to test whether hepcidin contributes to the develop-
ment of anemia in tumor-bearing mice, we injected two of the
Figure 5. ID8-bearing mice develop iron deficiency anemia. C57BL/6 mice were injected intraperitoneally with 16106 ID8 cells and
euthanized after 18.5 weeks. Compared to controls, ID8-bearing mice: (A) are more anemic; (B) have elevated ZPP levels; (C,D) have lower liver and
spleen iron levels. N = 10–16 mice per treatment and control group. *P,0.05, **P,0.001; P by Mann-Whitney rank-sum test (A,B) or student t-test
(C,D). Bars and error bars are median 6 median 675th/25th percentile (A,B) or mean 6 SD (C,D).
doi:10.1371/journal.pone.0093283.g005
Figure 6. ID8-bearing mice have decreased liver hepcidin mRNA responsive to decreased iron stores. At 18.5 weeks, ID8-bearing mice
compared to controls have (A) suppressed hepcidin mRNA; (B) significant positive correlation between liver iron stores and hepcidin mRNA
expression. N= 11–16 mice per treatment and control group. *P,0.05; P Mann-Whitney rank sum test in (A), and by Pearson Correlation in (B). Bars
and error bars are median 675th/25th percentile.
doi:10.1371/journal.pone.0093283.g006
Mouse Models of Anemia of Cancer
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tumor cell lines into hepcidin knockout mice. At day 14 after TC-1
injection, there was no significant difference between the
hemoglobin decreases of wild-type and hepcidin knockout mice
(Fig. 8A) (WT TC-1 21.08 g/dL vs. HKO TC-1 20.99 g/dL,
P= 0.908). Although TC-1 mice had mildly elevated levels of
hepcidin, hepcidin is clearly not essential for the development of
this anemia. Taken together with the increase in SAA-1 levels,
these data point to a hepcidin-independent inflammatory mech-
anism for anemia.
To examine whether hepcidin expression is necessary for the
development of iron deficiency in a more chronic model, we
compared the development of anemia in WT and hepcidin
knockout mice bearing ID8 ovarian cancer. At 18.5 weeks, there
was no significant difference between the hemoglobin decreases of
wild-type and hepcidin knockout mice treated with ID8 (Fig. 8C)
(WT ID8 25.26 g/dL vs. HKO ID8 24.50 g/dL, P= 0.739).
These data confirm our findings that ID8-bearing mice develop
anemia in response to bleeding and nutritional iron deficiency,
rather than a hepcidin-mediated inflammatory mechanism.
Discussion
Anemia of cancer (AC) is an often overlooked but important
manifestation of a malignancy. Even mild anemia has been shown
to adversely affect patient-reported quality of life (QOL) param-
eters [30]. Although a decreased hemoglobin is only one factor in
the development of depressed QOL measurements in cancer
patients, the improvement of anemia has been shown to have a
significant and direct correlation with overall QOL [31]. The
improvement in QOL with anemia treatment persisted regardless
of partial or complete response to any chemotherapy regimen.
Additionally, AC has been shown to be an independent negative
prognostic factor for survival time of cancer patients [32].
Despite the adverse effects of AC, it is under-recognized and
under-treated by physicians [33], in part because of the lack of safe
and effective therapies. Among potential treatments, red blood cell
transfusions are associated with immunosuppressive effects,
infection transmission, and transfusion reactions [34]. Erythropoi-
esis-stimulating agents, such as recombinant human erythropoie-
tin, have been associated with higher mortality rates in patients
with head and neck cancer, breast cancer, and non-small cell lung
cancer [35]. Preclinical models should facilitate the development
of safer and more effective treatments.
In the sparse literature on the role of hepcidin in AC, there is
some evidence that inflammation and increased hepcidin concen-
trations could contribute to AC. Butterfield et al. demonstrated
that serum hepcidin levels were markedly elevated in human
patients with hematologic or nonhematologic cancers, including
melanoma and lung cancers [36]. Another study of anemic cancer
patients by Ukarma et al. [37] demonstrated an inverse
relationship between hepcidin levels and a hemoglobin response
to epoetin therapy. This relationship between epoetin resistance
and increased hepcidin indicates a potential role of hepcidin in the
mechanism of AC development. Sasu et al. further stratified
anemic cancer patients into those with inflammatory, mixed, and
iron-deficiency anemias, using hematologic parameters and C-
reactive protein levels [38]. This stratification showed that the
inflamed patients had the highest levels of serum hepcidin,
followed by the patients with the mixed anemia. There was also a
direct correlation between the inflammatory markers (ferritin and
CRP) and hepcidin in the AC patients, suggesting a role of
inflammation-induced hepcidin increase in the pathogenesis of AC
in a subset of cancer patients with prominent inflammation.
We recently published a detailed characterization of a mouse
model that helped define the contribution of hepcidin in anemia of
inflammation (AI) [39]. After a single intraperitoneal injection of
heat-killed Brucella abortus, the mice developed a severe anemia
with the characteristics of AI: increased SAA-1 and hepcidin, and
iron restriction with increased tissue iron stores. Importantly,
hepcidin ablation resulted in a significantly milder anemia with
faster recovery of hemoglobin to normal. This work demonstrated
the significant contribution of hepcidin to the development of AI
in this mouse model.
Here we analyzed four mouse models of AC in order to
investigate the roles of inflammation and hepcidin. The findings
are summarized in Table 1. All three of the rapidly-growing
models developed an anemia that shares some of the character-
istics of AI: iron-restricted erythropoiesis, intact tissue iron stores,
and inflammation. Of the two lung cancer models, the LLC mice
had significantly worse anemia, iron restriction, and increase in
liver iron stores, all despite an apparently lower hepcidin level than
the TC-1 mice. However, we hypothesize that an earlier time
point would show an increased hepcidin level in the LLC mice,
followed by hepcidin suppression secondary to active erythropoi-
esis, as evidenced by the robust reticulocytosis seen at 14 days.
Another possible etiology for the lower hemoglobin in LLC mice
would be shortened erythrocyte lifespan. While the peripheral
blood smears did not show frank hemolysis, there were increased
erythrocyte membrane abnormalities in LLC mice that could
target them for early destruction by phagocytosis.
As TC-1 mice were the only group to have elevated hepcidin
levels despite the suppressive effect of accelerated erythropoiesis on
hepcidin, we hypothesized that the inflammatory anemia of this
model would be reversible by hepcidin ablation. However, there
was no difference in the development of anemia in the hepcidin-1
KO mice. This points to predominantly hepcidin-independent
factors in anemia development in these mice, which could include
erythropoietic suppression and decreased erythrocyte lifespan.
Figure 7. Peripheral blood smears from wild-type tumor and
control mice show no significant schistocytosis. (A) PBS control
(B) TC-1 (C) LLC (D) ID8.
doi:10.1371/journal.pone.0093283.g007
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The limitation of our study is that only a single time point, at
which the mice had advanced cancer, was analyzed for each AC
model. We cannot, therefore, eliminate the possibility that
hepcidin may play a minor role in the development of AC earlier
in the course of the disease. In addition, different mouse models of
AC are likely to display a wide spectrum of hepcidin involvement,
as is true in human cancers. While our specific models do not show
a vital role of hepcidin in the development of AC, the
characterization of different models could show stronger hepcidin
involvement.
The slow-growing model of ovarian cancer developed a frank
iron-deficiency anemia, likely secondary to hemorrhagic ascites
and long-term anorexia. In addition, SAA-1 levels were not
elevated, confirming that these mice developed an iron-deficiency
anemia rather than AI. Unsurprisingly, repeating this model in
hepcidin KO mice yielded no difference in the development of
anemia confirming the lack of hepcidin involvement in this model
of AC.
Much is yet to be understood about the development of anemia
in cancer patients. The characterization and manipulation of
Figure 8. Tumor-induced hemoglobin decrease in TC-1 or ID8 -bearing mice is not affected by hepcidin ablation. (A) By day 14, there
is no significant difference between the hemoglobin changes in TC-1-bearing wild-type and hepcidin knockout mice (P = 0.908). (B) Absolute
hemoglobin levels of mice shown in A. (C) By 18.5 weeks, there is no significant difference between the hemoglobin changes of ID8-bearing wild-
type and hepcidin knockout mice (P = 0.739). (D) Absolute hemoglobin levels of mice shown in C. N = 4–19 mice per treatment and control group. P
by t-test. Bars and error bars are mean 6 SD.
doi:10.1371/journal.pone.0093283.g008
Table 1. Summary of Mouse Models.
Tumor
Time Course
(weeks)
Terminal Hgb (g/
dL) Inflammation Iron Restriction Iron Stores Hepcidin Level
Effect of hepcidin
ablation
TC-1 2 14.2 Severe Present Increased Elevated None
LLC 2 7.8 Moderate Present Increased Low —
B16-F10 2 8.2 Severe Present — Low —
ID8 18.5 10.4 Absent Present Decreased Low None
doi:10.1371/journal.pone.0093283.t001
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mouse models of cancer should be useful for the exploration of
mechanisms and potential therapeutics for AC.
Supporting Information
Figure S1 SAA-1 expression in ovarian tumor-bearing
mice. By 18.5 weeks, the ID8-bearing and control mice have
comparable SAA-1 levels (P = 0.361). N= 11–16 mice per
treatment and control group. P by Mann-Whitney rank sum test.
Bars and error bars are median 675th/25th percentile.
(TIF)
Table S1 PCR Primers.
(TIF)
Acknowledgments
We are grateful to Dr. Oliver Dorigo, Department of Obstetrics &
Gynecology, UCLA, for his donation of murine ID8 cells and to Dr.
Sophie Vaulont, Institut Cochin, Institut National de la Sante´ et de la
Recherche Medicale, for providing our laboratory with the founder pairs of
Hamp12/2 mice.
Author Contributions
Conceived and designed the experiments: AK SR EN TG. Performed the
experiments: AK DS DL VG. Analyzed the data: AK SR DS DL EN TG.
Wrote the paper: AK EN TG.
References
1. Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in
cancer: a systematic review of the literature. Am J Med 116 Suppl 7A: 11S–26S.
2. Kosmidis P, Krzakowski M, Investigators E (2005) Anemia profiles in patients
with lung cancer: what have we learned from the European Cancer Anaemia
Survey (ECAS)? Lung Cancer 50: 401–412.
3. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, et al. (2002)
Relationship between changes in hemoglobin level and quality of life during
chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer
95: 888–895.
4. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S (2003) Cancer-related
fatigue: evolving concepts in evaluation and treatment. Cancer 98: 1786–1801.
5. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic
factor for survival in patients with cancer: a systemic, quantitative review.
Cancer 91: 2214–2221.
6. Dicato M, Plawny L, Diederich M (2010) Anemia in cancer. Ann Oncol 21
Suppl 7: vii167–172.
7. Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, et al. (2008)
Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res
14: 3262–3267.
8. Adamson JW (2008) The anemia of inflammation/malignancy: mechanisms and
management. Hematology/the Education Program of the American Society of
Hematology American Society of Hematology Education Program: 159–165.
9. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:
1011–1023.
10. Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary
antimicrobial peptide synthesized in the liver. J Biol Chem 276: 7806–7810.
11. Ganz T, Nemeth E (2012) Hepcidin and iron homeostasis. Biochim Biophys
Acta 1823: 1434–1443.
12. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. (2004)
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its
internalization. Science 306: 2090–2093.
13. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, et al. (2004) IL-6
mediates hypoferremia of inflammation by inducing the synthesis of the iron
regulatory hormone hepcidin. J ClinInvest 113: 1271–1276.
14. Wrighting DM, Andrews NC (2006) Interleukin-6 induces hepcidin expression
through STAT3. Blood 108: 3204–3209.
15. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, et al. (2007) STAT3 is
required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenter-
ology 132: 294–300.
16. Verga Falzacappa MV, Vujic SM, Kessler R, Stolte J, Hentze MW, et al. (2007)
STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation.
Blood 109: 353–358.
17. Songur N, Kuru B, Kalkan F, Ozdilekcan C, Cakmak H, et al. (2004) Serum
interleukin-6 levels correlate with malnutrition and survival in patients with
advanced non-small cell lung cancer. Tumori 90: 196–200.
18. Zakrzewska I, Poznanski J (2001) [Changes of serum il-6 and CRP after
chemotherapy in patients with ovarian carcinoma]. Pol Merkur Lekarski 11:
210–213.
19. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, et al. (2004) IL-6
mediates hypoferremia of inflammation by inducing the synthesis of the iron
regulatory hormone hepcidin. J Clin Invest 113: 1271–1276.
20. Ramos E, Kautz L, Rodriguez R, Hansen M, Gabayan V, et al. (2011) Evidence
for distinct pathways of hepcidin regulation by acute and chronic iron loading in
mice. Hepatology 53: 1333–1341.
21. Zhang Z, Zhang F, Guo X, An P, Tao Y, et al. (2012) Ferroportin1 in
hepatocytes and macrophages is required for the efficient mobilization of body
iron stores in mice. Hepatology 56: 961–971.
22. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, et al. (2000)
Development of a syngeneic mouse model for events related to ovarian cancer.
Carcinogenesis 21: 585–591.
23. Lesbordes-Brion JC, Viatte L, Bennoun M, Lou DQ, Ramey G, et al. (2006)
Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis.
Blood 108: 1402–1405.
24. Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, et al. (2012)
Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of
severe hemochromatosis. Blood 120: 3829–3836.
25. Goodnough JB, Ramos E, Nemeth E, Ganz T (2012) Inhibition of hepcidin
transcription by growth factors. Hepatology 56: 291–299.
26. Wong SS, Qutishat AS, Lange J, Gornet TG, Buja LM (1996) Detection of iron-
deficiency anemia in hospitalized patients by zinc protoporphyrin. Clin Chim
Acta 244: 91–101.
27. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, et al. (2004) IL-6 plays
a critical role in the synergistic induction of human serum amyloid A (SAA) gene
when stimulated with proinflammatory cytokines as analyzed with an SAA
isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res
Commun 314: 363–369.
28. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S (2006) Suppression of
hepcidin during anemia requires erythropoietic activity. Blood 108: 3730–3735.
29. Lynch EC (1990) Peripheral Blood Smear. In: Walker HK, Hall WD, Hurst JW,
editors. Clinical Methods: The History, Physical, and Laboratory Examinations.
3rd ed. Boston.
30. Demetri GD (2001) Anaemia and its functional consequences in cancer patients:
current challenges in management and prospects for improving therapy.
Br J Cancer 84 Suppl 1: 31–37.
31. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in
chemotherapy patients treated with epoetin alfa is independent of disease
response or tumor type: results from a prospective community oncology study.
Procrit Study Group. J Clin Oncol 16: 3412–3425.
32. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, et al. (2004)
The European Cancer Anaemia Survey (ECAS): a large, multinational,
prospective survey defining the prevalence, incidence, and treatment of anaemia
in cancer patients. Eur J Cancer 40: 2293–2306.
33. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, et al. (1997)
Impact of therapy with epoetin alfa on clinical outcomes in patients with
nonmyeloid malignancies during cancer chemotherapy in community oncology
practice. Procrit Study Group. J Clin Oncol 15: 1218–1234.
34. Aapro M, Spivak JL (2009) Update on erythropoiesis-stimulating agents and
clinical trials in oncology. Oncologist 14 Suppl 1: 6–15.
35. Spivak JL, Gascon P, Ludwig H (2009) Anemia management in oncology and
hematology. Oncologist 14 Suppl 1: 43–56.
36. Butterfield AM, Luan P, Witcher DR, Manetta J, Murphy AT, et al. (2010) A
dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem 56:
1725–1732.
37. Ukarma L, Johannes H, Beyer U, Zaug M, Osterwalder B, et al. (2009)
Hepcidin as a predictor of response to epoetin therapy in anemic cancer
patients. Clin Chem 55: 1354–1360.
38. Sasu BJ, Li H, Rose MJ, Arvedson TL, Doellgast G, et al. (2010) Serum hepcidin
but not prohepcidin may be an effective marker for anemia of inflammation (AI).
Blood Cells Mol Dis 45: 238–245.
39. Kim A, Fung E, Parikh SG, Valore EV, Gabayan V, et al. (2014) A mouse
model of anemia of inflammation: complex pathogenesis with partial
dependence on hepcidin. Blood 123: 1129–1136.
Mouse Models of Anemia of Cancer
PLOS ONE | www.plosone.org 9 March 2014 | Volume 9 | Issue 3 | e93283
